Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department reviews NHS England expenditure reports relating to the prescribing of puberty blockers for children; and whether (a) financial oversight and (b) risk assessments have been conducted since 2010.

All arms-length bodies, including NHS England, are held to high standards of financial responsibility and publish annual reports and accounts which are laid before Parliament.

Gonadotrophin releasing hormone analogues, or puberty blockers, have been prescribed to children under 16 years of age in England for licenced uses, for instance precocious puberty and endometriosis, and off label uses, such as gender dysphoria. The cost of prescribing drugs to a patient is met by the patient's integrated care board.

Regarding risks assessments conducted since 2010, in March 2024 NHS England published a suite of documentation relating to its decision to remove gonadotrophin releasing hormone analogues as a routine treatment option in the National Health Service for children under 18 years old with gender dysphoria. This documentation included a review of the published evidence, which concluded that there is very limited evidence about safety, risks, benefits, and outcomes for the use of this medication in children with gender dysphoria.

Restrictions on the sale and supply of these medicines via private and NHS prescriptions were introduced in May 2024. As part of that legislation the Government conducted a targeted consultation and sought advice on patient safety from the independent Commission on Human Medicines (CHM) and Cass Review.

The Government response to the consultation, the full report of the CHM, and the Cass review are available publicly, and respectively, at the following three links:

https://www.gov.uk/government/consultations/proposed-changes-to-the-availability-of-puberty-blockers-for-under-18s/outcome/governments-response-to-the-targeted-consultation-on-proposed-changes-to-the-availability-of-puberty-blockers

https://www.gov.uk/government/publications/chms-report-on-proposed-changes-to-the-availability-of-puberty-blockers/commission-on-human-medicines-report-on-proposed-permanent-order-to-restrict-the-sale-and-supply-of-gnrh-agonists-in-children-and-young-people-under-1

https://webarchive.nationalarchives.gov.uk/ukgwa/20250310143633/https://cass.independent-review.uk/